Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.
G Ferrari, W Humphrey, M J McElrath...
https://pubmed.ncbi.nlm.nih.gov/9037064Completed
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-11-04
76
Participants Needed
6
Research Sites
N/A
Total Duration
To evaluate the safety and immunogenicity of ALVAC-HIV MN120TMG (vCP205) in comparison to ALVAC-RG rabies glycoprotein (vCP65) as a control when administered in HIV-1 negative volunteers. ALVAC-HIV vCP205 is a second generation candidate vaccine that can be used to induce a humoral and cellular response against several antigens. This recombinant construct is based on the canarypox vector termed ALVAC and expresses gp120 of the HIV MN strain, plus the transmembrane portion of the LAI strain as well as gag and protease.
CONDITIONS
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers
You may qualify if you...
Inclusion Criteria
Volunteers must have:
Exclusion Criteria
Co-existing Condition:
Volunteers with the following symptoms or conditions are excluded:
Volunteers with the following prior conditions are excluded:
Prior Medication:
Excluded:
Prior Treatment:
Excluded:
Risk Behavior:
Excluded: Identifiable high-risk behavior for HIV infection, such as:
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Total: 6 locations
1
UAB AVEG
Birmingham, Alabama, United States, 35294
Status Unknown
2
JHU AVEG
Baltimore, Maryland, United States
Status Unknown
3
St. Louis Univ. School of Medicine AVEG
St Louis, Missouri, United States, 63104
Status Unknown
4
Univ. of Rochester AVEG
Rochester, New York, United States, 14642
Status Unknown
5
Vanderbilt Univ. Hosp. AVEG
Nashville, Tennessee, United States, 37232
Status Unknown
6
UW - Seattle AVEG
Seattle, Washington, United States, 98144
Status Unknown
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
N/A
Model
N/A
Primary Purpose
PREVENTION
Number of Arms
0
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
G Ferrari, W Humphrey, M J McElrath...
https://pubmed.ncbi.nlm.nih.gov/9037064M A Egan, W A Pavlat, J Tartaglia...
https://pubmed.ncbi.nlm.nih.gov/7769304L M Carruth, T F Greten, C E Murray...
https://pubmed.ncbi.nlm.nih.gov/10445814